A practical reference on Dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-24. Anything still debated is marked as such rather than presented as settled.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid, may form a loose cake |
| Solubility class | Soluble in water | Practically insoluble in nonpolar solvents |
| Storage temperature, solid | -20 °C or below | Desiccated and protected from light |
| Storage temperature, liquid | 2-8 °C | Refrigerated, not frozen |
| Typical identity method | LC-MS | Observed mass compared with calculated mass |
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Overall, according to a study in British Columbia, approximately 2.3 children per 100,000 births (1 in 43,000) have some form of glycogen storage disease. In the United States, they are estimated to occur in 1 per 20,000–25,000 births. Dutch incidence rate is estimated to be 1 per 40,000 births. While a Mexican incidence showed 6.78:1000 male newborns. Within the category of muscle glycogenoses (muscle GSDs), McArdle disease (GSD-V) is by far the most commonly diagnosed.
222Rn, 3.82 days, alpha decaying to... 218Po, 3.10 minutes, alpha decaying to... 214Pb, 26.8 minutes, beta decaying to... 214Bi, 19.9 minutes, beta decaying to... 214Po, 0.1643 ms, alpha decaying to... 210Pb, which has a much longer half-life of 22.3 years, beta decaying to... 210Bi, 5.013 days, beta decaying to... 210Po, 138.376 days, alpha decaying to... 206Pb, stable The radon equilibrium factor is the ratio between the activity of all short-period radon progenies (which are responsible for most of radon's biological effects), and the activity that would be at equilibrium with the radon parent. If a closed volume is constantly supplied with radon, the concentration of short-lived isotopes will increase until an equilibrium is reached where the overall decay rate of the decay products equals that of the radon itself. The equilibrium factor is 1 when both activities are equal, meaning that the decay products have stayed close to the radon parent long enough for the equilibrium to be reached, within a couple of hours. Under these conditions, each additional pCi/L of radon will increase exposure by 0.01 working level (WL, a measure of radioactivity commonly used in mining). These conditions are not always met; in many homes, the equilibrium factor is typically 40%; that is, there will be 0.004 WL of daughters for each pCi/L of radon in the air.
Michel Chrétien (born March 26, 1936) is a Canadian medical researcher specializing in neuroendocrinology research at the Institut de recherches cliniques de Montréal, or Clinical Research Institute of Montreal, (IRCM). He is a younger brother of former Canadian prime minister, Jean Chrétien.
Milanese resumed football activity only at a regional level, only to officially end it at the end of the 1945-1946 season. In 2021, after 75 years, a new project is initiated: from the union of three clubs from the south of Milan (Accademia Sandonatese and ACD Metanopoli Calcio) Football Club Milanese 1902 is born, whose first team plays in the fifth division of the Italian championship, with a regional youth sector. F.C. Milanese 1902 was recreated with the intention of giving continuity in the football field to its ancestor U.S. Milanese, taking up its history, logo, traditions and club colours. Right now, F.C. Milanese 1902 is playing at the non-professional level with a youth sector of regional level.
Sources: en.wikipedia.org
=== Wealth and assets === Morea has been listed in various publications among Indian film personalities with significant net worth. As of 2025, his net worth has been estimated at over US$150 million by some sources. He is reported to own several high-end vehicles, including models such as the Rolls Royce Ghost, BMW M8, Lamborghini Sián, Mercedes GLS, Porsche 911, Ford Endeavour, as well as motorcycles like the Harley-Davidson Forty-Eight, Royal Enfield Bullet 500, and Aprilia RSV4. Reports also indicate that he owns multiple residential properties in India and abroad.
Adrenomedullin (ADM) is a peptide hormone that plays an important role in various physiological processes throughout the human body. Initially discovered in 1993 from a pheochromocytoma, a tumor of the adrenal medulla, this 52-amino acid peptide is now recognized for its diverse effects, including vasodilation, regulation of blood pressure, and maintenance of the vascular system. ADM is widely expressed in tissues and also found in the circulation, exerting its influence on the cardiovascular, lymphatic, and endocrine systems, as well as demonstrating anti-inflammatory and tissue-protective properties. In humans, ADM is encoded by the ADM gene. A similar peptide named adreomedullin2 was reported in rats in 2004, which exhibits a similar function.
This protein is known to interact with multiple human proteins, verified via two-hybrid screening. A few notable examples include: LATS2: Negatively regulates YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting cell proliferation and promoting apoptosis. ZGPAT (Zinc finger CCCH-type with G patch domain-containing protein): A transcription repressor that negatively regulates expression of EGFR, a gene involved in cell proliferation, survival and migration, suggesting that it may act as a tumor suppressor. RCOR3 (REST Corepressor 3): A protein that may act as a component of a co-repressor complex that represses transcription It also interacts with viral proteins such as: Replicase polyprotein 1ab (SARS-CoV2): A multifunctional protein involved in the transcription and replication of viral RNAs. Protein E7 (Human Papillomavirus): Plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle.
Sources: en.wikipedia.org
=== Sentencing === In 1998, there were wide racial disparities in arrests, prosecutions, sentencing, and deaths. Black people, despite being only 13% of regular drug users, made up for 35% of drug arrests, 55% of convictions, and 74% of people sent to prison for drug possession crimes. Nationwide African-Americans were sent to state prisons for drug offenses 13 times more often than white men. Crime statistics show that in 1999 in the United States, blacks were far more likely to be targeted by law enforcement for drug crimes, and they received much stiffer penalties and sentences than whites. A 2000 study found that the disproportionality of black drug offenders in Pennsylvania prisons was unexplained by higher arrest rates, which suggested the possibility of operative discrimination in sentencing. A 2008 paper stated that drug use rates by blacks (7.4%) were comparable to those by whites (7.2%), and since there are far more whites than blacks, 72% of illegal drug users in America are white, and only 15% are black. According to Michelle Alexander, the author of The New Jim Crow and a professor of law at Stanford Law School, drug trading is done at similar rates all over the US, but most people arrested for it are colored. Together, blacks and Hispanics were 58% of all prisoners in 2008 but only one quarter of the US population. Most prisoners are arrested for drug related crime, and in at least 15 states, three quarters of them are black or Latino.
== US–EU trade war == In response to Operation Arctic Endurance and European countries' refusal to support his annexation of Greenland, Trump threatened to increase tariffs against several EU and NATO members, reigniting concerns of a US-EU trade war. Trump said he would impose tariffs on any trading partner that did not support American annexation of Greenland. In January 2026, he threatened Denmark, Norway, Sweden, France, Germany, the United Kingdom, the Netherlands, and Finland with tariffs of up to 25% tariffs until they supported his takeover of Greenland, stating that they had "journeyed to Greenland, for purposes unknown. This is a very dangerous situation for the Safety, Security, and Survival of our Planet". On 21 January, Trump announced that he would not impose the tariffs, having agreed to a deal with NATO secretary general Mark Rutte.
coli, but intestinal macrophages still do not release cytokines, even after phagocytosis. Also, intestinal macrophages do not express lipopolysaccharide (LPS), IgA, or IgG receptors. The lack of LPS receptors is important for the gut as the intestinal macrophages do not detect the microbe-associated molecular patterns (MAMPS/PAMPS) of the intestinal microbiome. Nor do they express IL-2 and IL-3 growth factor receptors.
Sources: en.wikipedia.org
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.
Mass spectrometry gives the observed molecular mass, which is compared with the calculated value for the expected sequence. Reversed-phase chromatography shows retention behaviour and main peak purity. Peptide mapping adds sequence-level confirmation when the question requires it.
Typical entries include appearance, chromatographic purity as area percent, observed mass, water or residual solvent content, and the analytical methods used. The document reflects the lot tested and the laboratory that performed the work. It does not by itself establish that the delivered vial matches the tested lot.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.